Vemurafenib regimen extends PFS in BRAF V600E-mutant metastatic colorectal cancer


January 13, 2021

2 min read


Disclosures: The NIH/NCI supported the study. Kopetz reports consultant/advisory roles with Amal Therapeutics, Amgen, AstraZeneca, Bayer Health, Biocartis, Boehringer Ingelheim, Boston Biomedical, EMD Serono, Eli Lilly, Genentech, Holy Stone Healthcare, Karyopharm Therapeutics, Merck, Navire Pharma, Novartis, Pierre Fabre and Redx Pharma; stock ownership in MolecularMatch and Navire Pharma; and institutional research funding from Amgen, Array BioPharma, Biocartis, Eli Lilly, EMD Serono, Genentech/Roche, MedImmune, Novartis and Sanofi. Please see the study for all other authors’ relevant financial disclosures.

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Back to Healio

The addition of vemurafenib to irinotecan and cetuximab improved PFS and response rates among patients with BRAF V600E-mutant metastatic colorectal cancer, according to study results published in Journal of Clinical Oncology.

“This research was prompted by an appreciation that BRAF inhibition alone was not active in [patients with colorectal cancer] due to an adaptive feedback through the EGFR pathway,” Scott Kopetz, MD, PhD, FACP, professor of gastrointestinal medical oncology at The University of Texas MD Anderson Cancer Center, told Healio. “While the EGFR pathway is not a critical pathway in BRAF-mutated colorectal cancer tumors, after inhibition of BRAF, the tumor rapidly adapts and increases signaling through EGFR to maintain growth signaling via the MAPK pathway.…

Want to know more click here go to health news source.

Follow us get Health Tips Update

Health Tips Language

Health Tips Categories

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.